Literature DB >> 18837430

Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.

Christopher C Porter1, Amy E Carver, Edythe A Albano.   

Abstract

Peripheral neuropathy is a well-known side effect of vincristine, a micro-tubule inhibitor commonly used to treat malignancies. Severe neurologic adverse events can occur in patients with Charcot-Marie-Tooth disease (CMT) treated with vincristine. Voriconazole is an antifungal agent used increasingly in children with malignancy. Because of its metabolism by hepatic p450 enzymes, voriconazole may inhibit the clearance of many medications, including vincristine. We report a case of vincristine related neuropathy that was exacerbated by voriconazole in a patient with previously undiagnosed, X-linked CMT. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18837430     DOI: 10.1002/pbc.21786

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

Review 1.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Authors:  Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh
Journal:  Mycoses       Date:  2011-11-29       Impact factor: 4.377

2.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

3.  Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole.

Authors:  Mark John-Yung Lin; Megan Rose Paul; Dennis John Kuo
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

4.  Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Authors:  Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier
Journal:  Clin Case Rep       Date:  2022-05-05

Review 5.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

6.  Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.

Authors:  Lihua Yang; Lihua Yu; Xinxin Chen; Yanqun Hu; Bin Wang
Journal:  Med Sci Monit       Date:  2015-06-07

Review 7.  The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.

Authors:  J Chad Hoyle; Michael C Isfort; Jennifer Roggenbuck; W David Arnold
Journal:  Appl Clin Genet       Date:  2015-10-19

8.  Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.

Authors:  M Dorchin; R Masoumi Dehshiri; S Soleiman; M Manashi
Journal:  Iran J Ped Hematol Oncol       Date:  2013-10-22

9.  Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy.

Authors:  Naoto Okada; Takeshi Hanafusa; Takumi Sakurada; Kazuhiko Teraoka; Toshihide Kujime; Masahiro Abe; Yasuo Shinohara; Kazuyoshi Kawazoe; Kazuo Minakuchi
Journal:  J Clin Med Res       Date:  2014-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.